2016
DOI: 10.1016/j.abb.2016.02.014
|View full text |Cite
|
Sign up to set email alerts
|

Structural analysis of the TKB domain of ubiquitin ligase Cbl-b complexed with its small inhibitory peptide, Cblin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 7 publications
(7 citation statements)
references
References 21 publications
0
4
0
Order By: Relevance
“…High-resolution structures of the TKB domains of Cbl and Cbl-b are nearly identical (for example, Protein Data Bank [PDB] codes: 3PFV, 3VGO, and 3ZNI; see also Ohno et al. , 2016 ) and do not provide clues to explain the different efficiency and/or strength of Cbl and Cbl-b interactions with the pY1045 motif observed in our experiments.…”
Section: Resultsmentioning
confidence: 77%
“…High-resolution structures of the TKB domains of Cbl and Cbl-b are nearly identical (for example, Protein Data Bank [PDB] codes: 3PFV, 3VGO, and 3ZNI; see also Ohno et al. , 2016 ) and do not provide clues to explain the different efficiency and/or strength of Cbl and Cbl-b interactions with the pY1045 motif observed in our experiments.…”
Section: Resultsmentioning
confidence: 77%
“…44 As a RF ubiquitin ligase, the biological significance of CBLB enzymatic activity is a rapidly evolving area of research, with the discovery of its role in immunomodulation of the innate immune system published in 2014. 7,8,[45][46][47][48][49] This research activity highlights the need for small-molecule modulators of CBLB activity that can be used to better understand both the biology of this target in a research setting as well as those that can be translated into a clinical setting to improve disease outcomes. The experiments described in this article are the first published cell-free screen for modulators of CBLB enzymatic activity.…”
Section: Discussionmentioning
confidence: 99%
“…Two groups have reported peptidomimetic compounds that bind to the TKB domain of either CBL or CBLB, and block interaction with a specific substrate. 36,48,[51][52][53] These compounds are not catalytic inhibitors of E3 activity but rather allosteric agents that prevent specific substrates from being targeted by CBL or CBLB. Similarly to substrate peptidomimetics, Wu et al developed modified peptides based on the structure of the CBL RF interface with the E2 UbcH7.…”
Section: Discussionmentioning
confidence: 99%
“…The active site of casitas B-lineage lymphoma-b (Cbl-b), which is a ubiquitin ligase, is competitively blocked by a specific oligopeptide known as Cblin. Administration of Cblin suppresses IRS1 ubiquitination, prevents muscle atrophy, and retains normal insulin signals for muscle maintenance (18,19). Interestingly, glycinin, which is contained in 40% of SPI, possesses a sequence similar to the inhibitory peptide sequence of Cblin, and a 20% glycinin diet prevents muscle atrophy (7,12).…”
Section: Discussionmentioning
confidence: 99%